Sharemaestro Newsreel

Prestige Consumer Healthcare (NYSE:PBH) Upgraded by Zacks Research to "Hold" Rating

Zacks Research has upgraded Prestige Consumer Healthcare (NYSE:PBH) from a "strong sell" to a "hold" rating. This upgrade comes after the company exceeded quarterly earnings expectations, reporting $0.98 EPS against a $0.89 consensus and revenue of $265.71 million, a 6.5% increase year-over-year. The consensus …

Kamada Reports Record-High First Half and Second Quarter

Kamada Ltd. announced record-high financial results for the first half and second quarter of 2026, with double-digit growth in revenues and Adjusted EBITDA. The company reported first-half revenues of $100.2 million and Adjusted EBITDA of $25.7 million, and affirmed its 2026 annual guidance. This …

Kamada Announces Planned Transition of Chief Financial Officer

Kamada Ltd. announced that its Chief Financial Officer, Chaime Orlev, will transition out of his role effective December 31, 2026, to pursue other opportunities. Orlev has served as CFO since 2017 and will assist in the transition to his successor, for whom a search …

Kamada CFO Chaime Orlev to Exit Role After Nine Years

Kamada (NASDAQ: KMDA) announced that its Chief Financial Officer, Chaime Orlev, will step down on December 31, 2026, after nine years in the role, to pursue other opportunities. The company has initiated a search for his successor, and Orlev will provide transitional support. Kamada's …

Kamada reports record H1 revenues of $100.2M, up 13% YoY By Investing.com

Kamada Ltd. reported record first-half 2026 revenues of $100.2 million, marking a 13% increase year-over-year, driven by strong sales of KEDRAB, VARIZIG, and HEPAGAM. The biopharmaceutical company also announced a new three-year, $50 million plasma supply agreement and reaffirmed its annual revenue and adjusted …

Kamada (KMDA) delivers record H1 2026 growth and reaffirms double-digit 2026 guidance

Kamada Ltd. reported record financial results for the first half of 2026, with revenues of $100.2 million and adjusted EBITDA of $25.7 million, representing significant year-over-year growth. The company reaffirmed its full-year 2026 guidance for revenues between $200-$205 million and adjusted EBITDA of $50-$53 …

Kamada Secures 3-Year, ~$50M Plasma Deal; Sales Expected Q4

Liquidia Corp 2026: Revenue $171.68M, EPS $0.74— 10-Q Summary

Liquidia Corp reported strong financial results for the quarter ended 2026, with revenue reaching $171.68 million and diluted EPS of $0.74. This significant growth, representing an 1842.7% increase in revenue and 251% increase in diluted EPS year-over-year, was primarily driven by the successful commercial …

HC Wainwright Brokers Reduce Earnings Estimates for ETON

HC Wainwright has reduced its earnings per share estimates for Eton Pharmaceuticals (NASDAQ:ETON) for Q2 2026 and the full fiscal year 2026, lowering the Q2 estimate to $0.11 from $0.15 and the FY2026 estimate to $0.52, significantly below the broader consensus of $0.75. Despite …

(PCRX) and the Role of Price-Sensitive Allocations

This article analyzes Pacira Biosciences Inc

Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of "Hold" from Analysts

Lantheus Holdings, Inc. (NASDAQ:LNTH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $108.11. The company recently exceeded earnings and revenue expectations, reporting $1.55 EPS and $388.18 million in revenue. Institutional investors hold a significant 99.06% of the …

Hims & Hers Health (HIMS) Stock Looks Cheap Even With Legal Risk

Pacer Advisors Inc. Sells 484,736 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Pacer Advisors Inc. significantly reduced its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by selling 98.1% of its holdings, equating to 484,736 shares, and now owns 9,251 shares valued at approximately $279,000. Despite this reduction by one institutional investor, others have increased their positions, …

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Canopy Growth Corporation (NASDAQ:CGC) Given Consensus Recommendation of "Hold" by Analysts

Canopy Growth Corporation (NASDAQ:CGC) has received a consensus "Hold" rating from analysts, with two firms recommending a buy, two a hold, and one a sell. The company recently reported better-than-expected quarterly results, with a loss of $0.02 per share against an anticipated $0.04 loss, …

Assenagon Asset Management S.A. Grows Stock Holdings in Evolus, Inc. $EOLS

Assenagon Asset Management S.A. significantly increased its stake in Evolus, Inc. (NASDAQ:EOLS) by 51.8% in the second quarter, now holding 908,180 shares valued at approximately $6.3 million. This move is part of a trend among institutional investors, who collectively own 90.69% of Evolus stock. …

ETFs Investing in Viatris, Inc. Stocks

This article provides a comprehensive list of Exchange Traded Funds (ETFs) that hold Viatris, Inc. (VTRS) stocks, sorted by market value. It details various ETFs, including their issuer, management style, focus, expense ratio, assets under management (AUM), and 3-year NAV total return. The ETFs …

Canopy Growth Targets European Cannabis Expansion After MTL Deal and Cost Cuts

Canopy Growth (NASDAQ:CGC) is strategically refocusing on consumer cannabis, particularly in European markets and Canadian recreational cannabis, after significant restructuring, cost reductions, and the acquisition of MTL Cannabis. The company has seen growth across its businesses, including 20% in Canadian adult-use cannabis and 10% …

Takeda Pharmaceutical (TSE:4502) Is Using AI To Advance Three Late Stage Medicines

Takeda Pharmaceutical is leveraging AI and computational tools to enhance its drug discovery process, particularly for three late-stage medicines. This strategic shift is being led by its Chief Scientific Officer under new CEO leadership and aims to strengthen the company's product pipeline and R&D …

Dr. Reddy's Laboratories slides Wednesday, underperforms competitors

Dr. Reddy's Laboratories Ltd. shares fell 0.50% on Wednesday to 1,198.95 Indian rupees, underperforming the broader market as the BSE SENSEX Index dropped 0.24%. The company's stock closed 15.23% below its 52-week high achieved on June 29th.

Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Passes Above Two Hundred Day Moving Average - Should You Sell?

Cumberland Pharmaceuticals (NASDAQ:CPIX) shares recently surpassed their 200-day moving average, trading as high as $8.15 before settling at $7.96. Despite this technical indicator, analyst sentiment remains largely negative, with several firms issuing "sell" or "hold" ratings. The company also reported a disappointing quarter, missing …

TherapeuticsMD Q2 2026 License Revenue Drops 8.7% Year Over Year

TherapeuticsMD's Q2 2026 license revenue, primarily from the Mayne License Agreement, dropped 8.7% year over year to $864 thousand, leading to a 70% decline in net income from continuing operations. The company has fully exited research, development, and commercial operations, relying solely on this …

Alvotech (ALVO) to Announce Earnings on Wednesday

Alvotech (NASDAQ:ALVO) is set to release its Q2 2026 earnings on Wednesday, August 19th, with analysts forecasting a loss of $0.0526 per share and revenue of $103.0 million. The company's previous quarter reported a loss of $0.09 per share and $105.9 million in revenue, …

OGI Stock Builds Momentum As Sanity Group Delivers In Germany

Organigram Global Inc. (OGI) stock is trending up due to investor optimism driven by its newly acquired Sanity Group in Germany, which is meeting revenue expectations and holds approximately 10% market share with minimal exposure to adverse reimbursement changes. The company's core Canadian business …

Teva (TEVA) Is Up 6.0% After Moody’s Upgrade To Investment Grade And Higher 2026 Guidance

Teva Pharmaceutical Industries (TEVA) stock rose 6.0% following a Moody's upgrade to investment-grade Baa3 with a stable outlook, and increased 2026 revenue guidance to US$16.5 billion - US$16.85 billion. This upgrade reflects Teva's shift towards innovative medicines and debt reduction efforts, despite a Q2 …

ANI Pharma SVP, Generics Ori Gutwerg reports sale of 3,162 common shares worth $243,474

Ori Gutwerg, SVP of Generics at ANI Pharmaceuticals, sold 3,162 common shares for $77 each on August 10, totaling $243,474. This transaction reduced his holdings to 75,534 common shares. The information for this report was generated by AI from an SEC filing.

Aurora Cannabis to Review Takeover Bid From Rival Curaleaf

Aurora Cannabis is reviewing an unsolicited takeover bid from rival cannabis company Curaleaf Holdings worth approximately $272 million, or $4 per share. Aurora announced that it received letters from Curaleaf in late June and early July outlining the potential deal and plans to form …

Aurora Cannabis (ACB) Stock Soars Over 20% on a Proposed Takeover Bid from Curaleaf (CURLF)

Aurora Cannabis (ACB) stock surged over 20% following a proposed takeover bid from Curaleaf (CURLF). Curaleaf's offer values ACB stock at $4 per share, representing a 45% premium, and aims to combine operations across 17 countries, generating over $1.5 billion in revenue and creating …

ETON PHARMACEUTICALS INC : H.C. WAINWRIGHT RAISES TARGET PRICE TO $65 FROM $57

H.C. Wainwright has increased its target price for Eton Pharmaceuticals Inc. (ETON.O) to $65 from the previous $57. This adjustment reflects an updated outlook from the analyst firm regarding the company's valuation. The article also includes a disclaimer that its content is solely the …

ANI Pharmaceuticals (ANIP) SVP Ori Gutwerg sells 3,162 shares at $77

Ori Gutwerg, Senior Vice President of Generics at ANI Pharmaceuticals Inc. (ANIP), sold 3,162 shares of common stock at $77.00 per share on August 10, 2026. Following this transaction, Gutwerg directly holds 75,534 shares of the company's common stock. The sale, valued at $243,000, …

TherapeuticsMD Q2 2026 Earnings: License Revenue and Net Income Decline

TherapeuticsMD reported a decline in Q2 2026 license revenue and a significant drop in net income, while operating expenses slightly increased. The company continues to rely heavily on licensee performance and milestone payments, with an IMVEXXY milestone expected in Q3 2026. TherapeuticsMD is also …

Harrow (HROW) Stock Grapples With Losses Despite Double Digit Revenue Growth

Viatris Inc. (VTRS) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Viatris Inc. (VTRS) stock, including its current price, dividend information, and a collection of recent news articles. The news highlights Viatris's Q2 earnings performance, strategic moves like selling Tyrvaya, and analyst insights on its valuation …

Takeda Pharmaceutical (TSE:4502) Wins ORZEYFUL Approval, Where Does Fair Value Sit?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after U.S. regulators approved ORZEYFUL for adult narcolepsy type 1, and the company also issued new impairment …

Aquestive Therapeutics Q2 Loss Widens, Revenue Rises

Aquestive Therapeutics reported a wider net loss in Q2 compared to the previous year, despite an increase in total revenue. The company also updated its full-year 2026 outlook, anticipating total revenue to be between $58 million and $62 million, with non-GAAP adjusted EBITDA expected …

Hims & Hers (HIMS) Stock Rally Meets Margin Pressure And GAAP Loss